Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer

WHIPPANY, N.J., April 20 /PRNewswire/ -- As part of a Research and Development
partnership between Halo Pharmaceutical and DeMelleBioPharma, LLC, Dr. George
Bobotas joins Halo Pharmaceutical as Chief Scientific Officer. Halo and
DeMelle are working closely together in this alliance on the development of
several client products. "I am excited at the potential synergies between
these two dynamic companies and the opportunity to work closely together with
a talented group of pharmaceutical professionals," said Dr. George Bobotas.

Dr. Bobotas has been President and Managing Partner of DeMelleBioPharma, LLC
since 2008. He was employed at Reliant Pharmaceuticals (a wholly owned
subsidiary of GlaxoSmithKline plc) for eight years in the position of Vice
President, Scientific Affairs. At Reliant, he led teams for the development
and commercialization of products with combined marketing penetration of over
US$1.00 Billion including Lovaza and Antara among many others. Prior to
Reliant, he was the founder and Executive Director of the Covance Center for
CNS Research. Earlier in his career, Dr. Bobotas has held senior positions at
Mylan Laboratories, Somerset Pharmaceuticals and Forest Laboratories. He is
the inventor of 24 patents and patent applications. Dr. Bobotas received his
Ph.D. in Biochemistry from the City University of New York. He has also
received graduate training in Industrial Pharmacy and Physical Chemistry. He
is a member of the American Association of Pharmaceutical Scientists, American
College of Clinical Pharmacology and American Society for Experimental
Neurotherapeutics.

"Having Dr. Bobotas on its team, Halo now has the capability to develop more
complicated products and provide services to its existing and future clients
with challenging technical transfers and new Product Development
opportunities. We are excited to have George on board," said Mohd Asif, Chief
Financial Officer of Halo Pharmaceutical.

Halo capabilities include an impressive array of formulation services,
Commercial operations for solid dosage forms, and operations for the aseptic
filling of topical ointments, solid dosage forms(tablets and capsules),
liquids, suppositories, associated packaging (tablet, powder, liquids and HUD)
and ample laboratory space for formulation development, pre-clinical and
clinical supplies and support of commercial operations. An additional asset is
the site's capability to manufacture controlled substances (C2-C5) and an API
manufacturing unit with an outstanding track record of meeting DEA
requirements.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service,
specialty pharmaceutical company, offering state-of-the-art contract
manufacturing, early stage formulation development and laboratory services to
the pharmaceutical and related industries. Halo is currently a supplier of
choice to a number of large and medium size brand pharmaceutical companies for
important life cycle products. Contract manufacturing capabilities include
the ability to conduct aseptic filling, granulation, blending, tableting,
coating, packaging, and related warehousing operations. Halo Pharmaceutical
is a privately-held company.

About DeMelleBioPharma

DeMelle participates in new drug development through strategic alliances
across a broad range of pharmaceutical dosage forms and therapeutic areas. The
founders of DeMelle have a significant amount of experience in the
pharmaceutical industry. They were responsible in bringing a number of novel
drug products to commercialization.

SOURCE Halo Pharmaceutical

Mohd Asif, Chief Financial Officer, Halo Pharmaceutical, +1-973-428-4013,
masif@halopharma.com